Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of “Buy” by Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $220.00.

KRYS has been the subject of a number of analyst reports. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently bought and sold shares of the company. Entropy Technologies LP bought a new position in Krystal Biotech during the fourth quarter worth about $548,000. Janney Montgomery Scott LLC increased its holdings in shares of Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock worth $8,239,000 after buying an additional 15,545 shares in the last quarter. Principal Financial Group Inc. grew its position in Krystal Biotech by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company’s stock worth $19,340,000 after acquiring an additional 3,727 shares during the last quarter. abrdn plc raised its position in Krystal Biotech by 32.5% in the fourth quarter. abrdn plc now owns 57,033 shares of the company’s stock valued at $8,935,000 after purchasing an additional 13,979 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after buying an additional 433 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 0.1 %

Shares of KRYS stock opened at $169.13 on Friday. The stock’s fifty day simple moving average is $174.25 and its 200-day simple moving average is $172.13. The company has a market capitalization of $4.89 billion, a price-to-earnings ratio of 56.57 and a beta of 0.75. Krystal Biotech has a 1-year low of $141.72 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.30 earnings per share. On average, sell-side analysts predict that Krystal Biotech will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).